FIP (Feline Infectious Peritonitis) mRNA Vaccine

Abstract

Researchers at the University of California, Davis have developed an approach to combat Feline Infectious Peritonitis (FIP) through an in vitro-transcribed (IVT) RNA vaccine targeting the FCoV nucleocapsid (N) protein antigen.

Full Description

This technology introduces a novel vaccine strategy against FIP, a fatal disease in cats caused by feline coronavirus (FCoV). Utilizing in vitro-transcribed (IVT) RNA molecules that encode the FCoV nucleocapsid (N) protein antigen, this vaccine aims to provide a protective immune response in cats, potentially overcoming the challenges faced by previous vaccine attempts.

Applications

• Veterinary vaccines for domestic cats, particularly those in high-density environments like shelters and catteries. 
• Research tools in virology and immunology for studying FCoV and related coronaviruses. 
• Potential platform for developing similar vaccines against other coronaviruses in animals and humans.

Features/Benefits

• Targets FCoV N protein antigen with high amino acid sequence identity for broader protection. 
• Utilizes increased G/C content for enhanced expression. 
• Incorporates advanced LNP formulation for efficient delivery and immune response. 
• Designed to avoid antibody-dependent enhancement (ADE), increasing safety. 
• Addresses a critical need in veterinary medicine with no effective FIP vaccine currently available. 
• Addresses high mutation rate of FCoV leading to vaccine evasion.

Patent Status

Additional Patent Pending